FDA Approves Sanofi (France)-Regeneron Pharmaceuticals, Inc.'s Zaltrap for Metastatic Colorectal Cancer

The U.S. Food and Drug Administration said on Friday it had approved the Sanofi SA and Regeneron Pharmaceuticals Inc drug Zaltrap for patients with metastatic colorectal cancer whose tumors have failed to respond to earlier treatment with chemotherapy. The infused medicine, to be taken in combination with standard chemotherapy, will compete with Roche Holding AG's Avastin and Bristol-Myers Squibb Co's Erbitux. Industry analysts say they expect Zaltrap to win relatively wide use, but doubt it will overtake sales of those widely used older treatments.

Back to news